Showing results (31-40 of 46) with videos related to
Sort By:
Pageof 5
Bioorganic & Medicinal Chemistry Letters|May 14, 2010
Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead accountFrank Wu, Frank H Büttner, Rhonda Chen, et al.Bioorganic & Medicinal Chemistry Letters|August 4, 2010
Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 2, optimization for blood pressure reduction in spontaneously hypertensive ratsJohn D Ginn, Todd Bosanac, Rhonda Chen, et al.Journal of Medicinal Chemistry|December 17, 2009
Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinaseTina Morwick, Frank H Büttner, Charles L Cywin, et al.Journal of Neurointerventional Surgery|October 11, 2017
In-room assessment of intravascular velocity from time-resolved rotational angiography in patients with arteriovenous malformation: a pilot studyChung Jung Lin, Huai Che Yang, Ai Chi Chien, et al.NPJ Precision Oncology|December 10, 2025
Targeting high-risk MYC-overexpressed osteosarcoma with an Aurora kinase inhibitor:--results from a pilot umbrella trialKai Tian, Yafei Jiang, Mengxiong Sun, et al.Cancer Research|July 5, 2002
Angioarrestin: an antiangiogenic protein with tumor-inhibiting propertiesMohanraj Dhanabal, William J LaRochelle, Michael Jeffers, et al.Medical Decision Making : an International Journal of the Society for Medical Decision Making|June 14, 2021
Maximizing the Efficiency of Active Case Finding for SARS-CoV-2 Using Bandit AlgorithmsGregg S Gonsalves, J Tyler Copple, A David Paltiel, et al.ACS Medicinal Chemistry Letters|May 26, 2015
SAR and Structural Analysis of Siderophore-Conjugated Monocarbam Inhibitors of Pseudomonas aeruginosa PBP3Kerry E Murphy-Benenato, Brian Dangel, Hajnalka E Davis, et al.Cancer Research|May 1, 2002
Platelet-derived growth factor D: tumorigenicity in mice and dysregulated expression in human cancerWilliam J LaRochelle, Michael Jeffers, Jose R F Corvalan, et al.The Lancet. Gastroenterology & Hepatology|December 5, 2025
Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trialMilind Javle, Christos Fountzilas, Chih-Yi Liao, et al.Pageof 5